Chi­nese biotech aims $232M in IPO cash to push next-gen prostate can­cer drug; Im­munomedics rais­es near­ly a half-bil­lion off ap­proval

→ A Chi­nese can­cer-fo­cused biotech look­ing to one-up J&J and Pfiz­er in cas­tra­tion-re­sis­tant prostate can­cer has launched its IPO in Hong Kong, look­ing to raise more than $232 mil­lion (HK$1.86 bil­lion) on the HKEX. Three cor­ner­stone in­vestors have laid claims to $98 mil­lion worth of Kin­tor Phar­ma’s shares, while oth­ers are free to bid on the rest for be­tween HK$17.8 and HK$20.15 apiece. The Jiang­su-based com­pa­ny’s lead drug, prox­a­lu­tamide, is an an­dro­gen re­cep­tor an­tag­o­nist now in Phase III tri­als in Chi­na and Phase II in the US. The stock is sched­uled to de­but on May 22.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER